rift
valley
fever
viru
rvfv
zoonot
mosquitoborn
viru
belong
genu
phleboviru
famili
bunyavirida
caus
sever
diseas
human
livestock
throughout
arabian
rvfv
also
consid
potenti
bioterror
agent
last
decad
rift
valley
fever
rvf
outbreak
report
eastern
southern
africa
eg
kenya
somalia
unit
republ
tanzania
madagascar
south
africa
contrast
report
recent
occurr
rvf
western
central
africa
signific
high
lowpreval
cluster
rvf
subnat
area
african
contin
sinc
spread
rvfv
larg
depend
mosquito
vector
transloc
anim
host
endem
situat
usual
occur
restrict
geograph
area
inhabit
host
vector
nigeria
rvfv
antibodi
found
sheep
goat
cattl
hors
camel
northern
state
kaduna
plateau
suggest
viru
may
enzoot
nigeria
addit
serolog
studi
conduct
human
sera
confirm
exist
diseas
specif
geograph
locat
borno
state
northeastern
nigeria
share
intern
border
three
african
countri
cameroun
chad
niger
make
vulner
transboundari
spread
variou
diseas
includ
viral
hemorrhag
fever
vhf
addit
borno
state
report
nich
lassa
fever
viru
lasv
possibl
vhf
howev
epidemiolog
rvf
vhf
extens
investig
borno
state
detail
accur
investig
seropreval
necessari
ascertain
occurr
spread
rvf
area
rvfv
possess
singlestrand
tripartit
rna
genom
compos
three
segment
l
segment
encod
nucleocapsid
protein
np
nonstructur
ns
protein
use
ambisens
strategi
segment
encod
precursor
glycoprotein
gn
gc
two
nonstructur
protein
kda
kda
l
segment
encod
l
nucleotid
sequenc
np
gene
highli
conserv
among
variou
rvfv
serum
antibodi
np
readili
detect
earli
infect
convalesc
individu
provid
basi
diagnosi
tradit
diagnost
assay
vhf
base
immunoassay
use
live
virus
sourc
captur
antigen
use
highli
attenu
rvfv
requir
stringent
biosafeti
measur
could
readili
adopt
laboratori
develop
countri
infrastructur
biosafeti
level
contain
lack
use
recombin
viral
nucleoprotein
rnp
base
serolog
assay
iggelisa
immunofluores
assay
ifa
detect
antibodi
vhf
crimeancongo
hemorrhag
fever
viru
cchfv
lasv
recombin
protein
technolog
requir
high
contain
biosafeti
facil
could
readili
meet
demand
simpl
reliabl
system
diagnosi
vhf
also
compar
seroepidemiolog
variou
vhf
cohort
studi
studi
seropreval
rvfv
infect
human
borno
state
nigeria
determin
use
rnpbase
igg
elisa
preval
rvfv
antibodi
compar
hemorrhag
fever
viru
infect
includ
lasv
cchfv
addit
develop
viru
neutral
assay
use
vesicular
stomat
viru
vsv
pseudotyp
virusbear
glycoprotein
rvfv
use
vsv
pseudotyp
system
determin
high
throughput
screen
neutral
antibodi
rvfv
two
hundr
ninetyseven
serum
sampl
collect
septemb
februari
patient
attend
health
facil
govern
hospit
privat
hospit
clinic
local
govern
area
lga
borno
state
northern
nigeria
simpl
random
sampl
techniqu
use
obtain
human
sera
select
lga
consist
least
three
lga
three
senatori
district
north
central
south
also
town
lassa
insect
infect
recombin
baculovirus
express
rnp
rvfv
lasv
cchfv
produc
recombin
histag
rvfvrnp
lasvrnp
cchfvrnp
rnp
purifi
column
chromatographi
qiagen
gmbh
hilden
germani
describ
neg
control
antigen
prepar
baculoviru
lack
polyhedrin
express
use
protocol
rnp
express
histag
rnp
analyz
sdspage
gel
polyacrylamid
stain
coomassi
blue
biorad
laboratori
hercul
ca
usa
supplementari
figur
iggelisa
perform
describ
briefli
well
elisa
plate
coat
predetermin
optim
quantiti
purifi
rvfvrnp
lasvrnp
cchfvrnp
approxim
ngwell
overnight
well
plate
cover
pb
contain
skim
milk
tween
sigma
st
loui
mo
usa
pbstm
follow
incub
h
block
plate
wash
three
time
pb
contain
tween
pbst
inocul
test
serum
dilut
pbstm
h
incub
period
plate
wash
three
time
pbst
inocul
goat
antihuman
igg
antibodi
label
hrp
dilut
zyme
laboratori
inc
south
san
francisco
ca
usa
h
incub
period
plate
wash
abt
solut
roch
diagnost
mannheim
germani
ad
well
plate
incub
min
room
temperatur
optic
densiti
nm
measur
refer
nm
adjust
valu
calcul
subtract
valu
neg
agcoat
well
correspond
well
mean
plu
three
standard
deviat
elisa
indic
iggelisa
calcul
use
human
serum
sampl
confirm
neg
infect
respect
virus
ifa
data
shown
use
cutoff
valu
iggelisa
order
minim
falseposit
result
could
occur
singl
serum
dilut
igg
respons
consid
posit
sampl
show
adjust
valu
cutoff
dilut
convent
neutral
assay
use
infecti
rvfv
strain
perform
describ
briefli
heatinactiv
serum
sampl
dilut
threefold
eagl
minimum
essenti
medium
mem
sigma
st
loui
mo
usa
contain
fb
invitrogen
carlsbad
ca
usa
test
sampl
mix
volum
infecti
dose
plaqu
form
unit
mixtur
incub
h
neutral
incub
mixtur
test
neutral
cytopath
effect
inhibit
assay
use
vero
neutral
antibodi
nab
titer
defin
reciproc
highest
dilut
cytopath
effect
observ
glycoprotein
gp
cdna
clone
construct
rvfvgp
express
plasmid
design
gener
rvfvgpbear
vsv
pseudotyp
rvfvpv
encod
luciferas
gene
kindli
provid
dr
whitt
instead
vsvg
gene
inocul
human
kidney
transfect
h
cultur
supernat
collect
use
work
seed
rvfvpv
dilut
rvfvpv
use
calcul
produc
approxim
rel
light
unit
control
well
serum
sampl
mix
rvfvpv
dilut
mem
sigma
supplement
fb
invitrogen
mixtur
incub
h
neutral
serumrvfvpv
mixtur
transfer
plate
contain
monolay
vero
h
cell
lyse
luciferas
activ
measur
use
brightglo
luciferas
assay
system
promega
madison
wi
usa
accord
protocol
recommend
manufactur
sensit
specif
predict
valu
posit
neg
test
calcul
standard
method
spearman
rank
correl
coeffici
test
roc
curv
twographroc
tgroc
analyz
use
stat
flex
ver
softwar
program
artech
co
ltd
osaka
japan
order
determin
seropreval
rvfv
human
borno
state
nigeria
sera
first
subject
hisrvfvrnpbas
iggelisa
igg
respons
consid
posit
sampl
adjust
valu
higher
cutoff
valu
dilut
serum
sampl
analyz
posit
rvfv
igg
tabl
simultan
serum
sampl
also
test
presenc
antibodi
lasv
cchfv
use
rnpbase
igg
elisa
total
sampl
posit
antibodi
lasv
cchfv
respect
tabl
result
indic
high
preval
rate
rvf
studi
area
order
confirm
efficaci
rvfvrnp
antigen
determin
sensit
specif
rvfvrnp
base
elisa
nab
assay
perform
use
human
serum
sampl
examin
posit
nab
antibodi
titer
rang
tabl
thirtyon
sensit
nabposit
sampl
also
posit
iggelisa
specif
nabneg
sampl
also
neg
iggelisa
viru
neutral
assay
use
vsv
pseudotypebear
glycoprotein
virus
caus
vhf
develop
high
sensit
order
determin
whether
vsvbase
rvfv
pseudotyp
appli
screen
nab
rvfv
infect
produc
rvfvpv
determin
whether
human
sera
collect
studi
area
could
neutral
infect
singl
serum
dilut
assay
rather
titrat
endpoint
dilut
perform
order
establish
highthroughput
screen
nab
sinc
infect
rvfvpv
harbor
luciferas
gene
could
ascertain
determin
luciferas
activ
neutral
activ
sera
repres
percent
neutral
calcul
reduct
luciferas
express
serum
sampl
test
show
luciferas
activ
neutral
remain
show
less
neutral
compar
nonserum
control
tabl
sensit
rvfvpvbase
neutral
assay
determin
compar
result
obtain
convent
neutral
assay
use
serum
sampl
test
posit
neutral
assay
show
neutral
rvfvpv
tabl
furthermor
serum
sampl
less
neutral
none
posit
neutral
assay
tabl
roc
tgroc
analys
perform
order
select
cutoff
point
percent
neutral
use
rvfvpv
figur
cutoff
defin
intersect
point
sensit
specif
curv
cutoff
valu
neutral
sensit
specif
respect
cutoff
defin
neutral
sensit
would
increas
specif
would
decreas
figur
posit
correl
titer
neutral
antibodi
obtain
use
rvfvpv
obtain
use
convent
neutral
assay
spearman
rank
correl
coeffici
rs
calcul
figur
thu
nab
rvfv
screen
rvfvpvbase
neutral
assay
use
singl
serum
dilut
format
result
rnpbase
elisa
shown
approxim
studi
popul
borno
state
nigeria
histori
rvfv
infect
seropreval
rvf
higher
viral
hemorrhag
fever
lassa
fever
cchf
addit
rvfvpvbase
nab
assay
develop
studi
potenti
replac
tradit
assay
base
live
virus
diagnosi
seroepidemiolog
analysi
rvf
endem
nonendem
countri
